Epilepsy and Celiac Disease: Divergent Mechanisms, Diagnostic Pitfalls, and Therapeutic Implications - A Narrative Review
SN Comprehensive Clinical Medicine · 05.11.2026 · 8 (1)
DOI: 10.1007/s42399-026-02833-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift SN Comprehensive Clinical Medicine, online erschienen am 05.11.2026. Verfasst von Vito Evola und 3 weiteren Autor:innen. Die Arbeit nennt 48 Literaturangaben.
Abstract (Originalsprache)
Epilepsy is a neurological disorder defined by a predisposition to recurrent unprovoked seizures. In contrast, seizures occurring in the context of celiac disease (CD) may represent a heterogeneous spectrum, ranging from secondary/reactive events driven by systemic immune-metabolic disturbance to focal structural epilepsy in selected patients with enduring epileptogenic substrates. This distinction has important implications for clinical diagnosis and therapeutic decision-making. However, persistent seizures in CD should be interpreted phenotypically, because apparent anti-seizure medication (ASM) failure may reflect either untreated systemic drivers or, in selected patients with fixed structural lesions, true pharmacoresistant focal epilepsy. Emerging evidence indicates that, in the classic celiac disease–epilepsy–cerebral calcification (CEC) phenotype, seizures are often occipital in onset and may be associated with anti-transglutaminase 6 (TG6) antibodies. These seizures may be further potentiated by deficiencies in folate, vitamin B6, vitamin B12, and vitamin D, which can impair inhibitory neurotransmission, alter neuronal excitability, and disrupt myelin integrity. While epilepsy responds to ASMs that directly modulate neuronal excitability, seizure improvement and, in some cases, remission in patients with CD may require strict, sustained adherence to a gluten-free diet and correction of micronutrient deficits, with ASMs functioning as adjunctive rather than definitive therapy. This review examines CD-associated seizure phenotypes along a spectrum that may overlap with focal epilepsy, and delineates diagnostic strategies, including serologic testing, nutrient assessment, and neuroimaging, while highlighting the risk of misclassification when systemic autoimmunity is overlooked. Future directions include validating TG6 and related biomarkers, developing screening protocols for refractory epilepsy clinics, and conducting prospective trials evaluating combined ASM-gluten-free diet therapy. Clarifying these distinctions is essential for improving diagnostic accuracy, reducing unnecessary polypharmacy, and advancing a multidisciplinary framework for managing seizure disorders with autoimmune etiologies.
Zitieren
APA
Evola, V., Patel, S., John, N., & Parmar, M. S. (2026). Epilepsy and Celiac Disease: Divergent Mechanisms, Diagnostic Pitfalls, and Therapeutic Implications - A Narrative Review. SN Comprehensive Clinical Medicine, 8(1). https://doi.org/10.1007/s42399-026-02833-7
Vancouver
Evola V, Patel S, John N, Parmar MS. Epilepsy and Celiac Disease: Divergent Mechanisms, Diagnostic Pitfalls, and Therapeutic Implications - A Narrative Review. SN Comprehensive Clinical Medicine. 2026;8(1). doi:10.1007/s42399-026-02833-7
BibTeX
@article{Evola2026,
author = {Evola, Vito and Patel, Shivani and John, Nigel and Parmar, Mayur S.},
title = {Epilepsy and Celiac Disease: Divergent Mechanisms, Diagnostic Pitfalls, and Therapeutic Implications - A Narrative Review},
journal = {SN Comprehensive Clinical Medicine},
year = {2026},
volume = {8},
number = {1},
doi = {10.1007/s42399-026-02833-7}
}
EUVIMED